DelveInsight’s, “Atypical Teratoid Rhabdoid Tumors (ATRT) – Pipeline Insight, 2020,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
    Geography Covered
    • Global coverage
    Atypical Teratoid Rhabdoid Tumors (ATRT) Understanding
    Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
    Atypical Teratoid Rhabdoid Tumors (ATRT) is a rare and fast-growing malignant tumor of the central nervous system and spinal cord. ATRTs occur slightly more often in males than females. Mostly mutations in the tumor suppressor genes SMARCB1 or SMARCA4 is the leading cause of ATRTs and in some cases these mutations are inherited. ATRTs usually occur by age 3, but sometimes are found in older children and adults. Although ATRT is a relatively rare disease, accounting for less than 5% of all pediatric CNS tumors, up to 20% of malignant CNS tumors diagnosed before the patient is 3 years old are ATRTs.
    Symptoms
    The symptoms of Atypical Teratoid Rhabdoid Tumors (ATRT) include:
    • Morning headaches or headaches that are less painful after vomiting
    • Nausea and vomiting
    • Changes in activity levels
    • Feeling sleepy
    • Loss of balance, increasing problems with coordination or trouble walking
    • Asymmetric eye movements or face movements
    • Increase in head size (in infants)


Diagnosis
A diagnosis of typical Teratoid Rhabdoid Tumors (ATRT) is based upon a thorough clinical evaluation, and a variety of specialized tests. ATRT is most commonly diagnosed from imaging studies like Magnetic resonance imaging (MRI), Computerized tomography scan, Lumbar puncture, Ultrasound, and biopsy. Genetic testing can also be done to look for a specific genetic defect often associated with ATRT.
Treatment
Treatment for Atypical Teratoid Rhabdoid Tumors (ATRT) depends on the size and location of the tumor and also on the age of the patient. Available treatment options include surgery, chemotherapy and radiation therapy. Some new chemotherapy, targeted therapy, or immunotherapy drugs can be a possible emerging treatment option. High-dose chemotherapy with stem cell transplant is also done in some cases.
Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs Chapters
This segment of the Atypical Teratoid Rhabdoid Tumors (ATRT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs


  • • Tazemetostat: Epizyme
    Tazemetostat is an orally administered, first-in-class small molecule EZH2 inhibitor. Epizyme holds global development and commercialization rights to tazemetostat ex-Japan. Eisai owns development and commercialization rights to tazemetostat in Japan, and a right of first negotiation to rights in the rest of Asia.
    Further product details are provided in the report??..
    Atypical Teratoid Rhabdoid Tumors (ATRT): Therapeutic Assessment
    This segment of the report provides insights about the different Atypical Teratoid Rhabdoid Tumors (ATRT) drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Atypical Teratoid Rhabdoid Tumors (ATRT)
    There are approx. 6+ key companies which are developing the therapies for Atypical Teratoid Rhabdoid Tumors (ATRT). The companies which have their Atypical Teratoid Rhabdoid Tumors (ATRT) drug candidates in the most advanced stage, i.e. phase III include, Epizyme.
    • Phases
    DelveInsight’s report covers around 6+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • intravitreal
    • Subretinal
    • Topical.
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type


Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atypical Teratoid Rhabdoid Tumors (ATRT): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Teratoid Rhabdoid Tumors (ATRT) drugs.


Report Highlights


  • • The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Teratoid Rhabdoid Tumors (ATRT) R&D. The therapies under development are focused on novel approaches to treat/improve Atypical Teratoid Rhabdoid Tumors (ATRT).
    Atypical Teratoid Rhabdoid Tumors (ATRT) Report Insights
    • Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs
    Atypical Teratoid Rhabdoid Tumors (ATRT) Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Atypical Teratoid Rhabdoid Tumors (ATRT) drugs?
    • How many Atypical Teratoid Rhabdoid Tumors (ATRT) drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atypical Teratoid Rhabdoid Tumors (ATRT)?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Atypical Teratoid Rhabdoid Tumors (ATRT) and their status?
    • What are the key designations that have been granted to the emerging drugs?
    Key Players
    • Takeda Oncology
    • Epizyme
    • Vyriad Inc.
    • Novartis Oncology
    • DNAtrix
    • Pfizer
    • Oncoceutics
    • Istari Oncology Inc.

    Key Products
    • Alisertib
    • Tazemetostat
    • Modified Measles Virus (MV-NIS)
    • Ribociclib
    • Trametinib
    • Tasadenoturev
    • Palbociclib
    • ONC-206
    • Polio/Rhinovirus Recombinant (PVSRIPO)